Sarepta Therapeutics

FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy
FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy
BioSpace
FDA
Sarepta Therapeutics
DMD
gene therapy
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Sarepta: FDA finds ‘no significant safety issues of concern’ with DMD gene therapy
Sarepta: FDA finds ‘no significant safety issues of concern’ with DMD gene therapy
Biopharma Reporter
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
gene therapy
FDA
Flag link:
Sarepta's DMD gene therapy inches closer to market as FDA declines to hold advisory meeting
Sarepta's DMD gene therapy inches closer to market as FDA declines to hold advisory meeting
Fierce Biotech
FDA
Sarepta Therapeutics
SRP-9001
gene therapy
DMD
Duchenne Muscular Dystrophy
Flag link:
Biopharma's stock market winners of 2022 revealed
Biopharma's stock market winners of 2022 revealed
EP Vantage
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
Flag link:
JPM Day 1: Highlights
JPM Day 1: Highlights
BioSpace
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Flag link:
Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal
Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal
Endpoints
Sarepta Therapeutics
SRP-9001
gene therapy
Duchenne Muscular Dystrophy
CDMOs
Catalent
Flag link:
Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment
Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment
Fierce Biotech
Hansa Biopharma
clinical trials
imlifidase
transplants
Sarepta Therapeutics
Flag link:
FDA grants speedy review to Sarepta’s Duchenne gene therapy
FDA grants speedy review to Sarepta’s Duchenne gene therapy
BioPharma Dive
Sarepta Therapeutics
SRP-9001
FDA
Duchenne Muscular Dystrophy
Flag link:
FDA preps for DMD drug generics as Sarepta has yet to finish its confirmatory trial
FDA preps for DMD drug generics as Sarepta has yet to finish its confirmatory trial
Endpoints
Sarepta Therapeutics
generics
Duchenne Muscular Dystrophy
FDA
eteplirsen
Flag link:
Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod
Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
gene therapy
Flag link:
Few safe havens surface in another down quarter for biopharma
Few safe havens surface in another down quarter for biopharma
EP Vantage
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Flag link:
The gloom deepens for biopharma stocks
The gloom deepens for biopharma stocks
EP Vantage
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Flag link:
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
BioPharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
gene therapy
SRP-9001
Flag link:
Pepgen aims to overtake Sarepta
Pepgen aims to overtake Sarepta
EP Vantage
Sarepta Therapeutics
PepGen
Duchenne Muscular Dystrophy
PGN-ED051
Flag link:
Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability
Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Flag link:
After serious side effect, Sarepta and FDA realign on next-gen Duchenne drug with trial hold lifted
After serious side effect, Sarepta and FDA realign on next-gen Duchenne drug with trial hold lifted
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
vesleteplirsen
clinical trials
Flag link:
Did Sarepta Therapeutics Just Unveil a Breakthrough?
Did Sarepta Therapeutics Just Unveil a Breakthrough?
TheStreet.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
Flag link:
Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy
Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy
BioSpace
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Flag link:
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Fierce Biotech
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Roche
accelerated approvals
Flag link:

Pages